Using Microbiome Transplantation or FMT for RCC They should still benefit from their given immunotherapy with additional supplements
Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses tUsing Microbiome Transplantation or FMT for RCC They should still benefit from their given immunotherapy with additional supplements at...
Author: Genitourinary-Cancer-Meeting
Added: 02/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 15, 2018 Category: Cancer & Oncology Source Type: podcasts
Overlooked Biomarker May Predict Cancer Immunotherapy Response
Dr David Kerr on data showing that tumors with extensive aneuploidy may not benefit as much from immune checkpoint blockade. (Source: Medscape Oncology)
Source: Medscape Oncology - February 15, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
Next Steps for Immunotherapies, Cell Therapies in Oncology
At ESMO 2017, Drs Zimmermann, Svane, and Coukos discuss successes and setbacks in immuno-oncology. (Source: Medscape Pathology and Laboratory Medicine Podcast)
Source: Medscape Pathology and Laboratory Medicine Podcast - February 9, 2018 Category: Laboratory Medicine Authors: Medscape Source Type: podcasts
Lung cancer immunotherapy test standardization: the Blueprint PD-L1 IHC Assay Comparison Project
With the increasing use of immunotherapy, methods of response testing need to be rigorous and comparable. However, as explained here by Fred Hirsch, MD, PhD, of University of Colorado, Denver, CO, the...
Author: VJOncology
Added: 02/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Unanswered questions in lung cancer immunotherapy
There are many areas of uncertainty surround immunotherapy, which require further exploration in the coming years. Speaking from the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held...
Author: VJOncology
Added: 02/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Hot topic: optimal immunotherapy combinations for lung cancer
Now that there is a range of immunotherapies available, the next frontier to explore is immunotherapy combination regimens. In this interview, Fred Hirsch, MD, PhD, of University of Colorado, Denver, ...
Author: VJOncology
Added: 02/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Lung cancer immunotherapy response testing: PDL-1, TMB or an alternative?
At the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland, Fred Hirsch, MD, PhD, of University of Colorado, Denver, CO, gave a very interesting talk on predictive r...
Author: VJOncology
Added: 02/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Tumor mutational burden (TMB): a predictive biomarker for lung cancer immunotherapy response
Tumor mutational burden (TMB) is emerging as a promising predictive biomarker for lung cancer immunotherapy response. Here, Fred Hirsch, MD, PhD, of University of Colorado, Denver, CO, discusses the d...
Author: VJOncology
Added: 02/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Immunotherapy: will we reach a point where we can curatively treat advanced NSCLC?
With the great promise that immunotherapy holds, there are hopes that it will revolutionize the treatment of lung cancer. Here, Solange Peters, MD, PhD, of Lausanne University Hospital, Lausanne, Fran...
Author: VJOncology
Added: 02/05/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 5, 2018 Category: Cancer & Oncology Source Type: podcasts
Lung cancer immunotherapy trial data to look forward to in 2018
With exciting data for immuno-oncology in lung cancer, there is much anticipation for what 2018 holds. In this interview, Solange Peters, MD, PhD, of Lausanne University Hospital, Lausanne, France, up...
Author: VJOncology
Added: 02/05/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 5, 2018 Category: Cancer & Oncology Source Type: podcasts
Paradigm-changing immunotherapy for advanced NSCLC: the PACIFIC and beyond
Immunotherapy is an exciting area for lung cancer, with numerous possibilities and game-changing potential. Speaking from the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dub...
Author: VJOncology
Added: 02/05/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 5, 2018 Category: Cancer & Oncology Source Type: podcasts
The role of immunotherapy in the radical treatment of NSCLC: where are we headed?
After many negative trial results for non-small cell lung cancer (NSCLC) therapies for some time, the field is now evolving in a very promising direction fast. Here, Solange Peters, MD, PhD, of Lausan...
Author: VJOncology
Added: 02/05/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 5, 2018 Category: Cancer & Oncology Source Type: podcasts
The role of pharmacists in the adoption of novel cancer immunotherapies
As traditional treatments for cancer are being surpassed by immunotherapies, the way in which healthcare providers deliver services must change. Speaking from the British Oncology Pharmacy Association...
Author: VJOncology
Added: 01/30/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 30, 2018 Category: Cancer & Oncology Source Type: podcasts
The impact of novel NSCLC immunotherapies
The landscape of NSCLC treatment is evolving rapidly. In this interview, Yvonne Summers, BSc, MB ChB, MSc, PhD, FRCP from The Christie NHS Foundation Trust, Manchester, UK, discusses exciting novel im...
Author: VJOncology
Added: 01/30/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 30, 2018 Category: Cancer & Oncology Source Type: podcasts
CD40 Antibody APX005M, Nivolumab & amp; Chemotherapy Phase 1b 2 Study to Explore Combo Chemotherapy and 2 Immunotherapy Agents
David Feltquate Head of Early Clinical Development at BRISTOL-MYERS SQUIBB discusses the the phase 1b/2 open-label study which will explore the combination of standard chemotherapy and two immunothera...
Author: Cancer-News
Added: 01/25/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 25, 2018 Category: Cancer & Oncology Source Type: podcasts
